vs
Neptune Insurance Holdings Inc.（NP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Neptune Insurance Holdings Inc.的季度营收约是REGENXBIO Inc.的1.2倍（$37.8M vs $30.3M），Neptune Insurance Holdings Inc.净利率更高（0.1% vs -221.3%，领先221.5%），REGENXBIO Inc.同比增速更快（43.0% vs 28.8%）
海王星保险控股有限公司是一家专业保险控股企业，主要经营财产及意外伤害保险业务，核心产品覆盖美国市场的住宅与商业洪水保险，服务个人消费者及中小型商业客户，依托数据分析实现精准定价和高效风险管理。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NP vs RGNX — 直观对比
营收规模更大
NP
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出14.2%
28.8%
净利率更高
NP
高出221.5%
-221.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.8M | $30.3M |
| 净利润 | $50.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 0.1% | -221.3% |
| 营收同比 | 28.8% | 43.0% |
| 净利润同比 | 0.0% | -31.2% |
| 每股收益（稀释后） | $0.05 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NPRGNX
| Q1 26 | $37.8M | — | ||
| Q4 25 | — | $30.3M | ||
| Q3 25 | $44.4M | $29.7M | ||
| Q2 25 | — | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | $33.8M | $24.2M | ||
| Q2 24 | — | $22.3M |
净利润NPRGNX
| Q1 26 | $50.0K | — | ||
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $11.5M | $-61.9M | ||
| Q2 25 | — | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $12.1M | $-59.6M | ||
| Q2 24 | — | $-53.0M |
毛利率NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | -190.0% | ||
| Q3 25 | 46.7% | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | 58.6% | -256.6% | ||
| Q2 24 | — | -251.3% |
净利率NPRGNX
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | -221.3% | ||
| Q3 25 | 25.9% | -208.3% | ||
| Q2 25 | — | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 35.8% | -246.3% | ||
| Q2 24 | — | -237.7% |
每股收益（稀释后）NPRGNX
| Q1 26 | $0.05 | — | ||
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $0.06 | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $0.06 | $-1.17 | ||
| Q2 24 | — | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $102.7M |
| 总资产 | — | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | $12.2M | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M |
总债务NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $247.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $102.7M | ||
| Q3 25 | $-509.5M | $161.5M | ||
| Q2 25 | — | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | $-374.3M | $301.4M | ||
| Q2 24 | — | $348.3M |
总资产NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $453.0M | ||
| Q3 25 | $89.6M | $525.2M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | — | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $38.9M | $-56.0M | ||
| Q2 25 | — | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | — | $-45.5M |
自由现金流NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M |
自由现金流率NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% |
资本支出强度NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% |
现金转化率NPRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.38× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NP
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
